Metronidazole vs placebo
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
48 questions · 48 findings · 1 reviews · Skin · Headline outcomes only
No studies found 14 · 29.2%GRADE not reported 1 · 2.1%Very low 0 · 0%Low 10 · 20.8%Moderate 12 · 25%High 11 · 22.9%
Metronidazole vs placebo
Participant‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
- no estimate extracted3 studies · 252 participantsModerate
Metronidazole vs placebo
Proportion of participants with adverse event · Participants with rosacea
Metronidazole showed no clear difference in proportion of participants with adverse event compared with placebo (high certainty).
1 finding from 1 review
- RR 1.19 [0.94, 1.51]6 studies · 1773 participantsHigh
Metronidazole vs placebo
Physician‐assessed improvement in rosacea severity · Participants with rosacea
Metronidazole probably leads to higher physician‐assessed improvement in rosacea severity compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.98 [1.29, 3.02]3 studies · 334 participantsModerate
Metronidazole vs placebo
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
- no estimate extracted7 studies · 602 participantsModerate
Metronidazole vs placebo
Lesion count · Participants with rosacea
1 finding from 1 review
- no estimate extracted8 studies · 1964 participantsModerate
Metronidazole vs placebo
Time needed until improvement of the skin lesions · Participants with rosacea
1 finding from 1 review
- no estimate extracted5 studies · 514 participantsHigh
Metronidazole vs placebo
Duration of remission · Participants with rosacea
Metronidazole probably leads to lower duration of remission compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.5 [0.25, 0.99]1 study · 88 participantsModerate
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel
Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel
Proportion of participants with adverse event · Participants with rosacea
Doxycycline 40 mg + metronidazole 1% gel may leads to lower proportion of participants with adverse event compared with doxycycline 100 mg + metronidazole 1% gel (low certainty).
1 finding from 1 review
- RR 0.25 [0.11, 0.54]1 study · 91 participantsLow
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel
Physician‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
- no estimate extracted1 study · 91 participantsLow
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
- no estimate extracted1 study · 91 participantsLow
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel
Lesion count · Participants with rosacea
1 finding from 1 review
- no estimate extracted1 study · 91 participantsLow
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel
Time needed until improvement of the skin lesions · Participants with rosacea
1 finding from 1 review
- no estimate extracted1 study · 91 participantsLow
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Topical metronidazole vs oral (oxy)tetracycline
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Topical metronidazole vs oral (oxy)tetracycline
Participant‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
- no estimate extracted3 studies · 182 participantsModerate
Topical metronidazole vs oral (oxy)tetracycline
Proportion of participants with adverse event · Participants with rosacea
1 finding from 1 review
- no estimate extracted4 studies · 258 participantsModerate
Topical metronidazole vs oral (oxy)tetracycline
Physician‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
- no estimate extracted2 studies · 81 participantsModerate